Boulder, Colorado (PRWEB) December 31, 2012
Centagen, Inc. has announced a new discovery that allows for the expansion of a person's own adult stem cells up to a million times without aging. The company believes this will greatly improve treatment for many types of chronic pain, disability and diseases. This might even be a real beginning at reversing the aging process since it supplies the body with a large number of one's own rejuvenated stem cells to rebuild organs and tissues that have been damaged by aging, injury or disease. Even better this type of adult stem cell therapy could be available fairly soon.
Each of us has a limited supply of the kind of stem cells needed to rebuild, repair, and rejuvenate any part of our body. As we age, the supply and healing power of our stem cells diminishes. By providing a practically unlimited supply of one's own rejuvenated stem cells, we may keep people young and healthy for well over a century. In particular, regenerating tissues and organs prepared by expanding one’s own stem cells could help with Alzheimer’s disease, diabetes, immune senescence, damaged heart tissue, arteriosclerosis, failing kidneys, failing hearing or eyesight, osteoporosis, weak muscles, and aged skin.
The technology requires no genetic engineering of the stem cells, so the procedure is much safer than the current procedures requiring genetic tampering. Only a patient’s adult stem cells are used, so there are no ethical issues common with embryonic stem cell use or side effects due to tissue rejection by your immune system.
Centagen has recently opened a crowd funding bid at http://www.indiegogo.com/centagen in concert with Maximum Life foundation, whose mission is to make “100 years old the new 50”.
Forward-Looking Statements for Centagen, Inc.
This press release contains several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy of stem cell therapeutics. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors and the Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control. The Company may not update these forward-looking statements in a timely manner as conditions change.